Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

IMPORTANCE: Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Raut, Chandrajit P., Espat, N. Joseph, Maki, Robert G., Araujo, Dejka M., Trent, Jonathan, Williams, Toni Faith, Purkayastha, D. Das, DeMatteo, Ronald P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440723/
https://ncbi.nlm.nih.gov/pubmed/30383140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4060
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados